Patents by Inventor Gloria Forkuo

Gloria Forkuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators
    Patent number: 12054491
    Abstract: The present invention describes substituted benzo[f]imidazo[1,5-a][1,4]diazepines of the formula (I): wherein R1, R2, R2?, R3, and X are as disclosed herein. These compounds target alpha-4 and alpha-5 GABAa receptors and are useful for the treatment of airway hyperresponsiveness and inflammation in asthma.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: August 6, 2024
    Assignees: UWM Research Foundation, Inc., The Trustees of Columbia University in the City of New York
    Inventors: Alexander E. Arnold, Douglas C. Stafford, James M. Cook, Charles W. Emala, Gloria Forkuo, Rajwana Jahan, Revathi Kodali, Guanguan Li, Michael Rajesh Stephen
  • GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA
    Publication number: 20230103216
    Abstract: Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 30, 2023
    Inventors: Alexander E. Arnold, Douglas C. Stafford, James M. Cook, Charles W. Emala, Gloria Forkuo, Rajwana Jahan, Revathi Kodali, Guanguan Li, Michael Rajesh Stephen
  • Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators
    Patent number: 11447495
    Abstract: Substituted benzo[f]imidazo[1,5-?][1,4]diazepines of formula (I?) target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: September 20, 2022
    Assignees: UWM Research Foundation, Inc., The Trustees of Columbia University in the City of New York
    Inventors: Alexander E. Arnold, Douglas C. Stafford, James M. Cook, Charles W. Emala, Gloria Forkuo, Rajwana Jahan, Revathi Kodali, Guanguan Li, Michael Rajesh Stephen
  • GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA
    Publication number: 20210284649
    Abstract: Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.
    Type: Application
    Filed: August 16, 2017
    Publication date: September 16, 2021
    Inventors: Alexander E. Arnold, Douglas C. Stafford, James M. Cook, Charles W. Emala, Gloria Forkuo, Rajwana Jahan, Revathi Kodali, Guanguan Li, Michael Rajesh Stephen